3idy › Citations

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD
Science 326 1123-7 (2009)
Related entries: 3hi1, 3idx

Cited: 228 times
EuropePMC logo PMID: 19965434

Abstract

The site on HIV-1 gp120 that binds to the CD4 receptor is vulnerable to antibodies. However, most antibodies that interact with this site cannot neutralize HIV-1. To understand the basis of this resistance, we determined co-crystal structures for two poorly neutralizing, CD4-binding site (CD4BS) antibodies, F105 and b13, in complexes with gp120. Both antibodies exhibited approach angles to gp120 similar to those of CD4 and a rare, broadly neutralizing CD4BS antibody, b12. Slight differences in recognition, however, resulted in substantial differences in F105- and b13-bound conformations relative to b12-bound gp120. Modeling and binding experiments revealed these conformations to be poorly compatible with the viral spike. This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies.

Articles - 3idy mentioned but not cited (5)

  1. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. Science 326 1123-1127 (2009)
  2. Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. Mata-Fink J, Kriegsman B, Yu HX, Zhu H, Hanson MC, Irvine DJ, Wittrup KD. J Mol Biol 425 444-456 (2013)
  3. A complete, multi-level conformational clustering of antibody complementarity-determining regions. Nikoloudis D, Pitts JE, Saldanha JW. PeerJ 2 e456 (2014)
  4. Asymmetric conformations of cleaved HIV-1 envelope glycoprotein trimers in styrene-maleic acid lipid nanoparticles. Wang K, Zhang S, Go EP, Ding H, Wang WL, Nguyen HT, Kappes JC, Desaire H, Sodroski J, Mao Y. Commun Biol 6 535 (2023)
  5. Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice. Chen X, Schmidt SD, Duan H, Doria-Rose NA, Mascola JR. STAR Protoc 3 101180 (2022)


Reviews citing this publication (46)

  1. HIV-1 antiretroviral drug therapy. Arts EJ, Hazuda DJ. Cold Spring Harb Perspect Med 2 a007161 (2012)
  2. HIV-1 neutralizing antibodies: understanding nature's pathways. Mascola JR, Haynes BF. Immunol Rev 254 225-244 (2013)
  3. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Kwong PD, Mascola JR. Immunity 37 412-425 (2012)
  4. Broadly neutralizing antiviral antibodies. Corti D, Lanzavecchia A. Annu Rev Immunol 31 705-742 (2013)
  5. The role of antibodies in HIV vaccines. Mascola JR, Montefiori DC. Annu Rev Immunol 28 413-444 (2010)
  6. A Blueprint for HIV Vaccine Discovery. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. Cell Host Microbe 12 396-407 (2012)
  7. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. Checkley MA, Luttge BG, Freed EO. J Mol Biol 410 582-608 (2011)
  8. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Walker LM, Burton DR. Curr Opin Immunol 22 358-366 (2010)
  9. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Kwong PD, Mascola JR, Nabel GJ. Cold Spring Harb Perspect Med 1 a007278 (2011)
  10. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Julien JP, Lee PS, Wilson IA. Immunol Rev 250 180-198 (2012)
  11. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G. Curr HIV Res 11 378-387 (2013)
  12. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Girard MP, Osmanov S, Assossou OM, Kieny MP. Vaccine 29 6191-6218 (2011)
  13. HIV-1 envelope glycoprotein structure. Merk A, Subramaniam S. Curr Opin Struct Biol 23 268-276 (2013)
  14. Development of prophylactic vaccines against HIV-1. Schiffner T, Sattentau QJ, Dorrell L. Retrovirology 10 72 (2013)
  15. Designing the next generation of vaccines for global public health. Bagnoli F, Baudner B, Mishra RP, Bartolini E, Fiaschi L, Mariotti P, Nardi-Dei V, Boucher P, Rappuoli R. OMICS 15 545-566 (2011)
  16. The changing face of HIV vaccine research. Kwong PD, Mascola JR, Nabel GJ. J Int AIDS Soc 15 17407 (2012)
  17. Structure-based vaccine design in HIV: blind men and the elephant? Pejchal R, Wilson IA. Curr Pharm Des 16 3744-3753 (2010)
  18. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Medina-Ramírez M, Sanders RW, Sattentau QJ. Curr Opin HIV AIDS 12 241-249 (2017)
  19. Strategies for eliciting HIV-1 inhibitory antibodies. Tomaras GD, Haynes BF. Curr Opin HIV AIDS 5 421-427 (2010)
  20. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD. Curr Opin HIV AIDS 8 382-392 (2013)
  21. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. Sadanand S, Suscovich TJ, Alter G. Annu Rev Med 67 185-200 (2016)
  22. HIV vaccine design: the neutralizing antibody conundrum. Stamatatos L. Curr Opin Immunol 24 316-323 (2012)
  23. Is developing an HIV-1 vaccine possible? Haynes BF, Liao HX, Tomaras GD. Curr Opin HIV AIDS 5 362-367 (2010)
  24. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. Benjelloun F, Lawrence P, Verrier B, Genin C, Paul S. J Virol 86 13152-13163 (2012)
  25. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Wu X, Kong XP. Curr Opin Immunol 42 56-64 (2016)
  26. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Acharya P, Lusvarghi S, Bewley CA, Kwong PD. Expert Opin Ther Targets 19 765-783 (2015)
  27. Structural Vaccinology for Viral Vaccine Design. Anasir MI, Poh CL. Front Microbiol 10 738 (2019)
  28. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Pu J, Wang Q, Xu W, Lu L, Jiang S. Viruses 11 E705 (2019)
  29. HIV/AIDS Vaccines: 2018. Robinson HL. Clin Pharmacol Ther 104 1062-1073 (2018)
  30. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  31. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Kepler TB, Wiehe K. Immunol Rev 275 129-144 (2017)
  32. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Sattentau QJ. Vaccines (Basel) 1 497-512 (2013)
  33. Immunogen design to focus the B-cell repertoire. Sattentau QJ. Curr Opin HIV AIDS 9 217-223 (2014)
  34. Candidate antibody-based therapeutics against HIV-1. Gong R, Chen W, Dimitrov DS. BioDrugs 26 143-162 (2012)
  35. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS. Virol Sin 28 71-80 (2013)
  36. Monoclonal antibody-based candidate therapeutics against HIV type 1. Chen W, Dimitrov DS. AIDS Res Hum Retroviruses 28 425-434 (2012)
  37. Closing the door to human immunodeficiency virus. Kang Y, Guo J, Chen Z. Protein Cell 4 86-102 (2013)
  38. Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. Flemming J, Wiesen L, Herschhorn A. AIDS Res Hum Retroviruses 34 794-803 (2018)
  39. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Griffith SA, McCoy LE. Front Immunol 12 708227 (2021)
  40. Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection. Sack B, Kappe SH, Sather DN. Expert Rev Vaccines 16 403-414 (2017)
  41. How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses? Makvandi-Nejad S, Rowland-Jones S. Immunol Lett 163 69-75 (2015)
  42. Broadly neutralizing antibodies and the promise of universal vaccines: where are we now? Hefferon KL. Immunotherapy 6 51-57 (2014)
  43. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Pathogens 10 685 (2021)
  44. Advances in HIV-1 Assembly. Lerner G, Weaver N, Anokhin B, Spearman P. Viruses 14 478 (2022)
  45. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Uversky VN. Arch Virol 166 1283-1296 (2021)
  46. [Structural mechanism of immune evasion of HIV-1 gp120 by genomic, computational, and experimental science]. Yokoyama M. Uirusu 61 49-57 (2011)

Articles citing this publication (177)

  1. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. Science 329 811-817 (2010)
  2. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. Science 333 1593-1602 (2011)
  3. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Nature 480 336-343 (2011)
  4. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Science 342 1477-1483 (2013)
  5. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature 514 455-461 (2014)
  6. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. Science 342 1484-1490 (2013)
  7. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. Science 340 1113-1117 (2013)
  8. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. Nat Struct Mol Biol 20 796-803 (2013)
  9. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schön A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, McDermott AB, Mascola JR, Kwong PD. Nat Struct Mol Biol 22 522-531 (2015)
  10. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. Proc Natl Acad Sci U S A 107 1166-1171 (2010)
  11. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. Proc Natl Acad Sci U S A 107 13800-13805 (2010)
  12. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. PLoS Pathog 7 e1001251 (2011)
  13. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS, NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD. Cell 161 1280-1292 (2015)
  14. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. Proc Natl Acad Sci U S A 109 5663-5668 (2012)
  15. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD. J Virol 84 8098-8110 (2010)
  16. Few and far between: how HIV may be evading antibody avidity. Klein JS, Bjorkman PJ. PLoS Pathog 6 e1000908 (2010)
  17. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD. Science 340 751-756 (2013)
  18. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. Abela IA, Berlinger L, Schanz M, Reynell L, Günthard HF, Rusert P, Trkola A. PLoS Pathog 8 e1002634 (2012)
  19. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD. Nat Med 24 857-867 (2018)
  20. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Garces F, Lee JH, de Val N, de la Pena AT, Kong L, Puchades C, Hua Y, Stanfield RL, Burton DR, Moore JP, Sanders RW, Ward AB, Wilson IA. Immunity 43 1053-1063 (2015)
  21. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Azoitei ML, Correia BE, Ban YE, Carrico C, Kalyuzhniy O, Chen L, Schroeter A, Huang PS, McLellan JS, Kwong PD, Baker D, Strong RK, Schief WR. Science 334 373-376 (2011)
  22. Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. Reguera J, Santiago C, Mudgal G, Ordoño D, Enjuanes L, Casasnovas JM. PLoS Pathog 8 e1002859 (2012)
  23. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, Chambers M, Chuang GY, DeKosky BJ, Doria-Rose NA, Druz A, Ernandes MJ, Georgiev IS, Jarosinski MC, Joyce MG, Lemmin TM, Leung S, Louder MK, McDaniel JR, Narpala S, Pancera M, Stuckey J, Wu X, Yang Y, Zhang B, Zhou T, NISC Comparative Sequencing Program, Mullikin JC, Baxa U, Georgiou G, McDermott AB, Bonsignori M, Haynes BF, Moore PL, Morris L, Lee KK, Shapiro L, Mascola JR, Kwong PD. Nat Struct Mol Biol 23 81-90 (2016)
  24. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, Chen RE, Louder MK, Pancera M, Wanninger TG, Zhang B, Zheng A, Farney SK, Foulds KE, Georgiev IS, Joyce MG, Lemmin T, Narpala S, Rawi R, Soto C, Todd JP, Shen CH, Tsybovsky Y, Yang Y, Zhao P, Haynes BF, Stamatatos L, Tiemeyer M, Wells L, Scorpio DG, Shapiro L, McDermott AB, Mascola JR, Kwong PD. Cell Rep 19 719-732 (2017)
  25. Immunology and the elusive AIDS vaccine. Virgin HW, Walker BD. Nature 464 224-231 (2010)
  26. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW. J Exp Med 214 2573-2590 (2017)
  27. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. PLoS Pathog 7 e1002209 (2011)
  28. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. Science 346 1380-1383 (2014)
  29. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB, Sodroski J. PLoS Pathog 7 e1002101 (2011)
  30. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, Trkola A. J Exp Med 208 439-454 (2011)
  31. Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U, Chen RE, Druz A, Lees CR, Narpala S, Schön A, Van Galen J, Chuang GY, Gorman J, Harned A, Pancera M, Stewart-Jones GB, Cheng C, Freire E, McDermott AB, Mascola JR, Kwong PD. J Virol 89 5318-5329 (2015)
  32. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar MG, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R, CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium. J Virol 87 7218-7233 (2013)
  33. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Günthard HF, Trkola A. J Exp Med 208 1419-1433 (2011)
  34. Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics. Abrams CF, Vanden-Eijnden E. Proc Natl Acad Sci U S A 107 4961-4966 (2010)
  35. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, Allhorn M, Evans DT. J Virol 86 12039-12052 (2012)
  36. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Mao Y, Wang L, Gu C, Herschhorn A, Désormeaux A, Finzi A, Xiang SH, Sodroski JG. Proc Natl Acad Sci U S A 110 12438-12443 (2013)
  37. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Diskin R, Marcovecchio PM, Bjorkman PJ. Nat Struct Mol Biol 17 608-613 (2010)
  38. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB. Sci Transl Med 4 142ra96 (2012)
  39. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B. PLoS Comput Biol 6 e1000955 (2010)
  40. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT. Proc Natl Acad Sci U S A 111 E738-47 (2014)
  41. Lessons learned from HIV-1 vaccine trials: new priorities and directions. McMichael AJ, Haynes BF. Nat Immunol 13 423-427 (2012)
  42. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, Soeta T, Kobayashi T, Princiotto AM, Wu X, Schön A, Freire E, Kwong PD, Mascola JR, Sodroski J, Madani N, Smith AB. J Med Chem 55 4382-4396 (2012)
  43. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J, Shao Y. Immunity 44 939-950 (2016)
  44. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. Xiang SH, Finzi A, Pacheco B, Alexander K, Yuan W, Rizzuto C, Huang CC, Kwong PD, Sodroski J. J Virol 84 3147-3161 (2010)
  45. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD. J Virol 91 e02268-16 (2017)
  46. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, Jankovic M, Corti D, Lanzavecchia A, Nussenzweig MC. J Exp Med 207 1995-2002 (2010)
  47. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. Chuang GY, Acharya P, Schmidt SD, Yang Y, Louder MK, Zhou T, Kwon YD, Pancera M, Bailer RT, Doria-Rose NA, Nussenzweig MC, Mascola JR, Kwong PD, Georgiev IS. J Virol 87 10047-10058 (2013)
  48. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA. J Virol 85 905-915 (2011)
  49. Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. Haim H, Salas I, Sodroski J. J Virol 87 1884-1889 (2013)
  50. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L. Nat Commun 8 1732 (2017)
  51. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT. J Biol Chem 287 5673-5686 (2012)
  52. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. Leaman DP, Kinkead H, Zwick MB. J Virol 84 3382-3395 (2010)
  53. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR. J Virol 85 2397-2405 (2011)
  54. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL, Ward AB, Li S, Wilson IA, Law M. Proc Natl Acad Sci U S A 113 12768-12773 (2016)
  55. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM. J Virol 86 947-960 (2012)
  56. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ. J Virol 87 10163-10172 (2013)
  57. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T. PLoS One 7 e33298 (2012)
  58. CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. Madani N, Princiotto AM, Schön A, LaLonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB, Wyatt R, Sodroski J. J Virol 88 6542-6555 (2014)
  59. Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Haim H, Salas I, McGee K, Eichelberger N, Winter E, Pacheco B, Sodroski J. Cell Host Microbe 14 547-558 (2013)
  60. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD. J Virol 85 2524-2535 (2011)
  61. Phenotypic Correlates of HIV-1 Macrophage Tropism. Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Rie AV, Cohen MS, Spudich S, Price RW, Montefiori DC, Swanstrom R. J Virol 89 11294-11311 (2015)
  62. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. Sun M, Pace CS, Yao X, Yu F, Padte NN, Huang Y, Seaman MS, Li Q, Ho DD. J Acquir Immune Defic Syndr 66 473-483 (2014)
  63. A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. Sethi A, Tian J, Derdeyn CA, Korber B, Gnanakaran S. PLoS Comput Biol 9 e1003046 (2013)
  64. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. Alsahafi N, Debbeche O, Sodroski J, Finzi A. PLoS One 10 e0122111 (2015)
  65. Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. Aldon Y, McKay PF, Allen J, Ozorowski G, Felfödiné Lévai R, Tolazzi M, Rogers P, He L, de Val N, Fábián K, Scarlatti G, Zhu J, Ward AB, Crispin M, Shattock RJ. Cell Rep 24 3324-3338.e5 (2018)
  66. HIV vaccine development--improving on natural immunity. Johnston MI, Fauci AS. N Engl J Med 365 873-875 (2011)
  67. Progress in the rational design of an AIDS vaccine. Nabel GJ, Kwong PD, Mascola JR. Philos Trans R Soc Lond B Biol Sci 366 2759-2765 (2011)
  68. Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising. Luo S, Perelson AS. Proc Natl Acad Sci U S A 112 11654-11659 (2015)
  69. Morphology and ultrastructure of retrovirus particles. Zhang W, Cao S, Martin JL, Mueller JD, Mansky LM. AIMS Biophys 2 343-369 (2015)
  70. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. J Virol 87 1137-1149 (2013)
  71. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. Kong L, Huang CC, Coales SJ, Molnar KS, Skinner J, Hamuro Y, Kwong PD. J Virol 84 10311-10321 (2010)
  72. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. J Virol 88 14002-14016 (2014)
  73. Conformational evaluation of HIV-1 trimeric envelope glycoproteins using a cell-based ELISA assay. Veillette M, Coutu M, Richard J, Batraville LA, Désormeaux A, Roger M, Finzi A. J Vis Exp 51995 (2014)
  74. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar R, Varadarajan R. J Biol Chem 285 27100-27110 (2010)
  75. Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections. Nourmohammad A, Otwinowski J, Plotkin JB. PLoS Genet 12 e1006171 (2016)
  76. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. Pancera M, Yang Y, Louder MK, Gorman J, Lu G, McLellan JS, Stuckey J, Zhu J, Burton DR, Koff WC, Mascola JR, Kwong PD. PLoS One 8 e55701 (2013)
  77. Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. Kong L, Sattentau QJ. J AIDS Clin Res S8 3 (2012)
  78. Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates. Verkerke HP, Williams JA, Guttman M, Simonich CA, Liang Y, Filipavicius M, Hu SL, Overbaugh J, Lee KK. J Virol 90 9471-9482 (2016)
  79. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. Castillo-Menendez LR, Witt K, Espy N, Princiotto A, Madani N, Pacheco B, Finzi A, Sodroski J. J Virol 92 e00277-18 (2018)
  80. Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. Furci L, Tolazzi M, Sironi F, Vassena L, Lusso P. PLoS One 7 e45208 (2012)
  81. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Wibmer CK, Gorman J, Anthony CS, Mkhize NN, Druz A, York T, Schmidt SD, Labuschagne P, Louder MK, Bailer RT, Abdool Karim SS, Mascola JR, Williamson C, Moore PL, Kwong PD, Morris L. J Virol 90 10220-10235 (2016)
  82. Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction. Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W. PLoS One 5 e10482 (2010)
  83. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. Davenport TM, Guttman M, Guo W, Cleveland B, Kahn M, Hu SL, Lee KK. J Virol 87 10855-10873 (2013)
  84. Accelerating HIV vaccine development. Koff WC. Nature 464 161-162 (2010)
  85. Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Schiffner T, de Val N, Russell RA, de Taeye SW, de la Peña AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ. J Virol 90 813-828 (2016)
  86. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L. J Virol 86 128-142 (2012)
  87. Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Acharya P, Luongo TS, Louder MK, McKee K, Yang Y, Kwon YD, Mascola JR, Kessler P, Martin L, Kwong PD. Structure 21 1018-1029 (2013)
  88. 3D visualization of HIV virions by cryoelectron tomography. Liu J, Wright ER, Winkler H. Methods Enzymol 483 267-290 (2010)
  89. Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Yacoob C, Pancera M, Vigdorovich V, Oliver BG, Glenn JA, Feng J, Sather DN, McGuire AT, Stamatatos L. Cell Rep 17 1560-1570 (2016)
  90. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM. J Virol 86 12115-12128 (2012)
  91. High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. Wang Y, Sundling C, Wilson R, O'Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, Karlsson Hedestam GB, Wyatt RT, Li Y. J Immunol 196 3729-3743 (2016)
  92. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Cimbro R, Gallant TR, Dolan MA, Guzzo C, Zhang P, Lin Y, Miao H, Van Ryk D, Arthos J, Gorshkova I, Brown PH, Hurt DE, Lusso P. Proc Natl Acad Sci U S A 111 3152-3157 (2014)
  93. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Ahmed FK, Clark BE, Burton DR, Pantophlet R. Vaccine 30 922-930 (2012)
  94. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. Navis M, Tran K, Bale S, Phad GE, Guenaga J, Wilson R, Soldemo M, McKee K, Sundling C, Mascola J, Li Y, Wyatt RT, Karlsson Hedestam GB. PLoS Pathog 10 e1004337 (2014)
  95. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120. Aneja R, Rashad AA, Li H, Kalyana Sundaram RV, Duffy C, Bailey LD, Chaiken I. J Med Chem 58 3843-3858 (2015)
  96. Antibody Heavy Chain Variable Domains of Different Germline Gene Origins Diversify through Different Paths. Kirik U, Persson H, Levander F, Greiff L, Ohlin M. Front Immunol 8 1433 (2017)
  97. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK, Kessler P, Yang Y, McKee K, O'Dell S, Chen L, Baty D, Chames P, Martin L, Mascola JR, Kwong PD. J Virol 87 10173-10181 (2013)
  98. In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells. Yokoyama M, Nomaguchi M, Doi N, Kanda T, Adachi A, Sato H. Front Microbiol 7 110 (2016)
  99. Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. McKinley SA, Chen A, Shi F, Wang S, Mucha PJ, Forest MG, Lai SK. PLoS One 9 e100598 (2014)
  100. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB. PLoS One 8 e72054 (2013)
  101. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Emileh A, Tuzer F, Yeh H, Umashankara M, Moreira DR, Lalonde JM, Bewley CA, Abrams CF, Chaiken IM. Biochemistry 52 2245-2261 (2013)
  102. Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. Rawi R, Rutten L, Lai YT, Olia AS, Blokland S, Juraszek J, Shen CH, Tsybovsky Y, Verardi R, Yang Y, Zhang B, Zhou T, Chuang GY, Kwong PD, Langedijk JPM. Cell Rep 33 108432 (2020)
  103. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. Liang Y, Guttman M, Williams JA, Verkerke H, Alvarado D, Hu SL, Lee KK. J Virol 90 9224-9236 (2016)
  104. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. Townsley S, Li Y, Kozyrev Y, Cleveland B, Hu SL. J Virol 90 829-841 (2016)
  105. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. Rathore U, Saha P, Kesavardhana S, Kumar AA, Datta R, Devanarayanan S, Das R, Mascola JR, Varadarajan R. J Biol Chem 292 10197-10219 (2017)
  106. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. Barbian HJ, Decker JM, Bibollet-Ruche F, Galimidi RP, West AP, Learn GH, Parrish NF, Iyer SS, Li Y, Pace CS, Song R, Huang Y, Denny TN, Mouquet H, Martin L, Acharya P, Zhang B, Kwong PD, Mascola JR, Verrips CT, Strokappe NM, Rutten L, McCoy LE, Weiss RA, Brown CS, Jackson R, Silvestri G, Connors M, Burton DR, Shaw GM, Nussenzweig MC, Bjorkman PJ, Ho DD, Farzan M, Hahn BH. mBio 6 e00296-15 (2015)
  107. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW. PLoS One 8 e76139 (2013)
  108. A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS. AlSalmi W, Mahalingam M, Ananthaswamy N, Hamlin C, Flores D, Gao G, Rao VB. J Biol Chem 290 19780-19795 (2015)
  109. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. Mikell I, Stamatatos L. PLoS One 7 e49610 (2012)
  110. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, Leaman DP, Phung P, Limoli K, Chen H, Boenig RI, Wrin T, Zwick MB, Whalen RG. PLoS One 8 e52732 (2013)
  111. Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. Liang Y, Guttman M, Davenport TM, Hu SL, Lee KK. Biochemistry 55 2197-2213 (2016)
  112. Probing the effect of force on HIV-1 receptor CD4. Perez-Jimenez R, Alonso-Caballero A, Berkovich R, Franco D, Chen MW, Richard P, Badilla CL, Fernandez JM. ACS Nano 8 10313-10320 (2014)
  113. HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Tuzer F, Madani N, Kamanna K, Zentner I, LaLonde J, Holmes A, Upton E, Rajagopal S, McFadden K, Contarino M, Sodroski J, Chaiken I. Proteins 81 271-290 (2013)
  114. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses. Taylor SD, Leib SR, Carpenter S, Mealey RH. J Virol 84 6536-6548 (2010)
  115. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120. Korkut A, Hendrickson WA. PLoS One 7 e52170 (2012)
  116. Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Arnold P, Himmels P, Weiß S, Decker TM, Markl J, Gatterdam V, Tampé R, Bartholomäus P, Dietrich U, Dürr R. Retrovirology 11 42 (2014)
  117. Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality. Hamoudi M, Simon-Loriere E, Gasser R, Negroni M. Retrovirology 10 114 (2013)
  118. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation. Guzzo C, Zhang P, Liu Q, Kwon AL, Uddin F, Wells AI, Schmeisser H, Cimbro R, Huang J, Doria-Rose N, Schmidt SD, Dolan MA, Connors M, Mascola JR, Lusso P. mBio 9 e00955-18 (2018)
  119. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang CI, Arendt HE, DeStefano J, Mascola JR, Wyatt RT, Li Y. J Immunol 197 3982-3998 (2016)
  120. AutoMatch: target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds. Zhang C, Lai L. Proteins 80 1078-1094 (2012)
  121. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, Barnett SW. PLoS One 7 e30233 (2012)
  122. Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. Sastry M, Xu L, Georgiev IS, Bewley CA, Nabel GJ, Kwong PD. J Biomol NMR 50 197-207 (2011)
  123. Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120. Shrivastava IH, Wendel K, LaLonde JM. Biochemistry 51 7783-7793 (2012)
  124. Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. Pan R, Chen Y, Vaine M, Hu G, Wang S, Lu S, Kong XP. Emerg Microbes Infect 4 e44 (2015)
  125. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding. Shrivastava I, LaLonde JM. Biochemistry 50 4173-4183 (2011)
  126. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development. Yuan T, Li J, Zhang Y, Wang Y, Streaker E, Dimitrov DS, Zhang MY. Vaccine 29 6903-6910 (2011)
  127. The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. Dueñas-Decamp MJ, O'Connell OJ, Corti D, Zolla-Pazner S, Clapham PR. Retrovirology 9 9 (2012)
  128. Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. Cimbro R, Peterson FC, Liu Q, Guzzo C, Zhang P, Miao H, Van Ryk D, Ambroggio X, Hurt DE, De Gioia L, Volkman BF, Dolan MA, Lusso P. EBioMedicine 10 45-54 (2016)
  129. Comment Vaccinology: A sweet cleft in HIV's armour. Sattentau QJ. Nature 480 324-325 (2011)
  130. Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein. Nguyen HT, Madani N, Ding H, Elder E, Princiotto A, Gu C, Darby P, Alin J, Herschhorn A, Kappes JC, Mao Y, Sodroski JG. Virol J 14 33 (2017)
  131. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Da LT, Quan JM, Wu YD. Proteins 79 1810-1819 (2011)
  132. Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. Rawi R, Kunji K, Haoudi A, Bensmail H. PLoS One 10 e0143245 (2015)
  133. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. Chuang GY, Lai YT, Boyington JC, Cheng C, Geng H, Narpala S, Rawi R, Schmidt SD, Tsybovsky Y, Verardi R, Xu K, Yang Y, Zhang B, Chambers M, Changela A, Corrigan AR, Kong R, Olia AS, Ou L, Sarfo EK, Wang S, Wu W, Doria-Rose NA, McDermott AB, Mascola JR, Kwong PD. J Virol 94 e00074-20 (2020)
  134. Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity. Wan C, Sun J, Chen W, Yuan X, Chong H, Prabakaran P, Dimitrov DS, He Y. PLoS One 8 e66638 (2013)
  135. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. Johnson J, Zhai Y, Salimi H, Espy N, Eichelberger N, DeLeon O, O'Malley Y, Courter J, Smith AB, Madani N, Sodroski J, Haim H. J Virol 91 e00174-17 (2017)
  136. Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120. Sang P, Yang LQ, Ji XL, Fu YX, Liu SQ. PLoS One 9 e104714 (2014)
  137. Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops. Moscoso CG, Xing L, Hui J, Hu J, Kalkhoran MB, Yenigun OM, Sun Y, Paavolainen L, Martin L, Vahlne A, Zambonelli C, Barnett SW, Srivastava IK, Cheng RH. Sci Rep 4 7025 (2014)
  138. A novel small-molecule inhibitor of HIV-1 entry. Heredia A, Latinovic OS, Barbault F, de Leeuw EP. Drug Des Devel Ther 9 5469-5478 (2015)
  139. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Ouyang Y, Yin Q, Li W, Li Z, Kong D, Wu Y, Hong K, Xing H, Shao Y, Jiang S, Ying T, Ma L. Sci Rep 7 6222 (2017)
  140. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. Qualls ZM, Choudhary A, Honnen W, Prattipati R, Robinson JE, Pinter A. J Virol 92 e01779-17 (2018)
  141. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody. Kenniston JA, Taylor BM, Conley GP, Cosic J, Kopacz KJ, Lindberg AP, Comeau SR, Atkins K, Bullen J, TenHoor C, Adelman BA, Sexton DJ, Edwards TE, Nixon AE. J Biol Chem 292 17449-17460 (2017)
  142. Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs. Witt KC, Castillo-Menendez L, Ding H, Espy N, Zhang S, Kappes JC, Sodroski J. PLoS One 12 e0170672 (2017)
  143. Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. Moyo T, Ferreira RC, Davids R, Sonday Z, Moore PL, Travers SA, Wood NT, Dorfman JR. Virology 501 12-24 (2017)
  144. Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies. Grimm SK, Battles MB, Ackerman ME. PLoS One 10 e0117227 (2015)
  145. Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols. Bailey LD, Kalyana Sundaram RV, Li H, Duffy C, Aneja R, Rosemary Bastian A, Holmes AP, Kamanna K, Rashad AA, Chaiken I. ACS Chem Biol 10 2861-2873 (2015)
  146. Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State. Zhang P, Kwon AL, Guzzo C, Liu Q, Schmeisser H, Miao H, Lin Y, Cimbro R, Huang J, Connors M, Schmidt SD, Dolan MA, Armstrong AA, Lusso P. mBio 12 e00090-21 (2021)
  147. Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. Kumar R, Visciano ML, Li H, Hioe C. J AIDS Clin Res S8 5512 (2012)
  148. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. Gift SK, Zentner IJ, Schön A, McFadden K, Umashankara M, Rajagopal S, Contarino M, Duffy C, Courter JR, Zhang MY, Gershoni JM, Cocklin S, Dimitrov DS, Smith AB, Freire E, Chaiken IM. Biochemistry 50 2756-2768 (2011)
  149. Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1. LaMont C, Otwinowski J, Vanshylla K, Gruell H, Klein F, Nourmohammad A. Elife 11 e76004 (2022)
  150. Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity? Olvera A, Cedeño S, Llano A, Mothe B, Sanchez J, Arsequell G, Brander C. Front Immunol 11 573928 (2020)
  151. Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines. Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA. Virol J 11 177 (2014)
  152. A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120. Emileh A, Abrams CF. Proteins 79 537-546 (2011)
  153. A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. Duan LW, Zhang H, Zhao MT, Sun JX, Chen WL, Lin JP, Liu XQ. Sci Rep 7 46733 (2017)
  154. CD4 binding determinant mimicry for HIV vaccine design. Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S. Front Immunol 3 383 (2012)
  155. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. Hager-Braun C, Hochleitner EO, Gorny MK, Zolla-Pazner S, Bienstock RJ, Tomer KB. J Am Soc Mass Spectrom 21 1687-1698 (2010)
  156. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy. Emileh A, Duffy C, Holmes AP, Rosemary Bastian A, Aneja R, Tuzer F, Rajagopal S, Li H, Abrams CF, Chaiken IM. Biochemistry 53 3403-3414 (2014)
  157. Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving. Andrianov AM. Expert Opin Drug Discov 6 419-435 (2011)
  158. Vaccine design reaches the atomic level. Kwong PD, Shapiro L. Sci Transl Med 3 91ps29 (2011)
  159. Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. Purwar M, Pokorski JK, Singh P, Bhattacharyya S, Arendt H, DeStefano J, La Branche CC, Montefiori DC, Finn MG, Varadarajan R. Vaccine 36 6345-6353 (2018)
  160. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. Galkin A, Chen Y, Guenaga J, O'Dell S, Acevedo R, Steinhardt JJ, Wang Y, Wilson R, Chiang CI, Doria-Rose N, Grishaev AV, Mascola JR, Li Y. J Immunol 204 1543-1561 (2020)
  161. Mathematical models: a key to understanding HIV envelope interactions? Magnus C, Brandenberg OF, Rusert P, Trkola A, Regoes RR. J Immunol Methods 398-399 1-18 (2013)
  162. Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. Frische A, Brooks PT, Gybel-Brask M, Sækmose SG, Jensen BA, Mikkelsen S, Bruun MT, Boding L, Strandh CP, Jørgensen CS, Krogfelt KA, Fomsgaard A, Lassauniere R. PLoS One 17 e0272298 (2022)
  163. Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe. Andrianov AM, Kornoushenko YV, Anishchenko IV, Eremin VF, Tuzikov AV. J Biomol Struct Dyn 31 665-683 (2013)
  164. Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. Zhou T, Chen L, Gorman J, Wang S, Kwon YD, Lin BC, Louder MK, Rawi R, Stancofski ED, Yang Y, Zhang B, Quigley AF, McCoy LE, Rutten L, Verrips T, Weiss RA, VRC Production Program, Doria-Rose NA, Shapiro L, Kwong PD. Structure 30 862-875.e4 (2022)
  165. Structure and design of broadly-neutralizing antibodies against HIV. Ryu SE, Hendrickson WA. Mol Cells 34 231-237 (2012)
  166. Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design. Hu D, Bowder D, Wei W, Thompson J, Wilson MA, Xiang SH. Vaccine 35 3067-3075 (2017)
  167. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner. Patil S, Choudhary I, Chaudhary NK, Ringe R, Bansal M, Shukla BN, Boliar S, Chakrabarti BK, Bhattacharya J. Virology 462-463 266-272 (2014)
  168. Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network. Shrivastava I, LaLonde JM. Proteins 78 2935-2949 (2010)
  169. Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. Bissa M, Forlani G, Zanotto C, Tosi G, De Giuli Morghen C, Accolla RS, Radaelli A. PLoS One 13 e0190869 (2018)
  170. HIV-1 envelope accessible surface and polarity: clade, blood, and brain. Sowmya G, Shamini G, Anita S, Sakharkar M, Mathura V, Rodriguez H, Levine AJ, Singer E, Commins D, Somboonwit C, Sinnott JT, Sidhu HS, Rajaseger G, Pushparaj PN, Kangueane P, Shapshak P. Bioinformation 6 48-56 (2011)
  171. Absolute quantitation of binding antibodies from clinical samples. Tang C, Verwilligen A, Sadoff J, Brandenburg B, Sneekes-Vriese E, van den Kerkhof T, Dillen L, Rutten L, Juraszek J, Callewaert K, Janssen S, Huizingh J, Euler Z, Schilperoord T, Verhemeldonck M, Langedijk JPM, Hendriks J, Stieh DJ. NPJ Vaccines 9 8 (2024)
  172. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Pilewski KA, Wall S, Richardson SI, Manamela NP, Clark K, Hermanus T, Binshtein E, Venkat R, Sautto GA, Kramer KJ, Shiakolas AR, Setliff I, Salas J, Mapengo RE, Suryadevara N, Brannon JR, Beebout CJ, Parks R, Raju N, Frumento N, Walker LM, Fechter EF, Qin JS, Murji AA, Janowska K, Thakur B, Lindenberger J, May AJ, Huang X, Sammour S, Acharya P, Carnahan RH, Ross TM, Haynes BF, Hadjifrangiskou M, Crowe JE, Bailey JR, Kalams S, Morris L, Georgiev IS. Cell Rep 42 112044 (2023)
  173. Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity. Kassler K, Sticht H. J Biomol Struct Dyn 32 52-64 (2014)
  174. Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120. Gift SK, McFadden K, Zentner IJ, Rajagopal S, Zhang MY, Dimitrov DS, Chaiken IM. Biochemistry 50 2769-2779 (2011)
  175. Revealing Novel-Strain-Specific and Shared Epitopes of Infectious Bronchitis Virus Spike Glycoprotein Using Chemical Linkage of Peptides onto Scaffolds Precision Epitope Mapping. Sives S, Keep S, Bickerton E, Vervelde L. Viruses 15 2279 (2023)
  176. RosettaSurf-A surface-centric computational design approach. Scheck A, Rosset S, Defferrard M, Loukas A, Bonet J, Vandergheynst P, Correia BE. PLoS Comput Biol 18 e1009178 (2022)
  177. Study on molecular mechanisms of CD4 dependency and independency of HIV-1 gp120. Liu MT, Shen JX, Li XW, Yang L, Li Y, Sang P, Yang LQ. RSC Adv 13 6274-6286 (2023)


Quick links